These DCs, matured and activated with immune-stimulating agents or TSAs, migrate to lymphatic tissues, where they engage with immune cells, presenting cancer antigens to CD4+ helper T cells and CD8+ cytotoxic T lymphocytes (CTLs), leading to their activation and subsequent elimination of cancer cells (32). This evidence concerns the gene CD8A and cancer.